TheraRadar
← Back
Data updated: Nov 8, 2026

SLATE RUN PHARMA

Generics
Pharmaceuticals

SLATE RUN PHARMA is a generic drug manufacturer with 2 FDA-approved products.

2006
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

SLATE RUN PHARMA's Key Drugs

SLATE RUN PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SLATE RUN PHARMA's Recent FDA Approvals

New NDA/BLA approvals for SLATE RUN PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SLATE RUN PHARMA's Therapeutic Areas

Disease areas where SLATE RUN PHARMA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

SLATE RUN PHARMA Pipeline Snapshot

Active clinical trials for SLATE RUN PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling